Global Ophthalmic Disease Therapeutic Market
Global Ophthalmic Disease Therapeutic Market was valued at USD 33.40 billion in 2021 which expected to reach USD 50.20 billion by 2027 at a CAGR 2.88% from 2022 to 2027.
Ophthalmic disease therapeutics are medications and therapies used to treat a variety of ocular illnesses, including glaucoma, dry eye disease, retinal diseases, and others. The market is anticipated to grow as a result of an increase in R&D activities by market participants to create novel treatments and medications.
Market Drivers
It is projected that the prevalence of ophthalmic illnesses in the population, including glaucoma, retinal diseases, dry eye disease, and others, will propel the expansion of the ophthalmic disease therapeutic market. For instance, according to an article written by the American Academy of Ophthalmology (AAO), glaucoma affects roughly 30 million people in the United States. Out of which, 2.7 million of them are senior citizens. Ocular disorders are becoming better known as a result of numerous initiatives launched by various healthcare organizations, governmental entities, and industry participants.
Rising R&D spending and activities by top players are anticipated to support the growth of the ophthalmic disease therapeutic market over the anticipated timeframe. One leading provider of eye care, Alcon, spent USD 842 million on R&D in 2021 as opposed to USD 673 in 2020. Alcon offers a wide range of products, including those for glaucoma, cataracts, and contact lenses. Furthermore, having a strong pipeline of skilled applicants would probably help the market expand. For instance, the phase III study for the novel NO donating PG analogue NCX 470 by Nicox, a novel eye therapeutics business, is projected to be completed by 2029.
Market Restraints
High cost of drugs is major restraining factor which expected to hamper the market growth over the forecast period. Therapeutics for ocular diseases are costly, rendering them unavailable to people with poor incomes or insufficient insurance coverage.
Furthermore, the process of obtaining regulatory approval for new drugs can be lengthy and costly. This can delay the introduction of new treatments to the market which expected to hinder the Global Ophthalmic Disease Therapeutic Market growth.
Market Segmentation
The Global Ophthalmic Disease Therapeutic Market is segmented into Drug Class such as Anti-Inflammatory, Antiallergy, Anti-VEGF, Anti-Glaucoma, and Others. By Dosage Form, market is segmented into Liquid, Solid, and Semi-solid. By Retinal Disease, market is segmented into Glaucoma, Dry Eye Disease, Retinal Diseases, Allergy & Infections, and Others.
Further, market is segmented into Distribution Channel such as Hospital Pharmacies and Retail & Online Pharmacies.
Regional Analysis
Global Ophthalmic Disease Therapeutic Market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Due to the rising prevalence of various ocular disorders and the greater rate of diagnosis and treatment, North America is anticipated to hold a significant market share for ophthalmic disease treatments. Along with increasing approval of novel treatments, there are favorable conditions and support available for the study and development of numerous revolutionary drugs to treat ocular illnesses. Loteprednol Etabonate Ophthalmic Gel, 0.5% was approved by the U.S. FDA in February 2021 for treating post-operative inflammation and pain following ocular surgery. It was manufactured by Akorn Operating Company LLC.
Key Developments
September 2022 Omlonti (omidenepag isopropyl ophthalmic solution) eye drops were given FDA approval by Santen Pharmaceutical Co., Ltd. and UBE. The eye drops are intended to lower excessive IOP in people with primary open-angle glaucoma or ocular hypertension.
Key Players
Regeneron Pharmaceuticals Inc, AbbVie Inc., Santen Pharmaceutical Co. Ltd., Novartis AG, Bayer AG, Viatris Inc, F. Hoffmann-La Roche Ltd., Alcon, Merck & Co., Inc, Pfizer Inc., etc.
Market Taxonomy
By Drug Class
• Anti-Inflammatory
• Antiallergy
• Anti-VEGF
• Anti-Glaucoma
• Others
By Dosage Form
• Liquid
• Solid
• Semi-solid
By Retinal Disease
• Glaucoma
• Dry Eye Disease
• Retinal Diseases
• Allergy & Infections
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail & Online Pharmacies
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa
Global Ophthalmic Disease Therapeutic Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Ophthalmic Disease Therapeutic Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply & Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Ophthalmic Disease Therapeutic Market, By Drug Class
5.1 Y-o-Y Growth Comparison, By Drug Class
5.2 Global Ophthalmic Disease Therapeutic Market Share Analysis, By Drug Class
5.3 Global Ophthalmic Disease Therapeutic Market Size and Forecast, By Drug Class
5.3.1 Anti-Inflammatory
5.3.2 Antiallergy
5.3.3 Anti-VEGF
5.3.4 Anti-Glaucoma
5.3.5 Others
6 Global Ophthalmic Disease Therapeutic Market, By Dosage Form
6.1 Y-o-Y Growth Comparison, By Dosage Form
6.2 Global Ophthalmic Disease Therapeutic Market Share Analysis, By Dosage Form
6.3 Global Ophthalmic Disease Therapeutic Market Size and Forecast, By Dosage Form
6.3.1 Liquid
6.3.2 Sold
6.3.3 Semi-Solid
7 Global Ophthalmic Disease Therapeutic Market, By Retinal Disease
7.1 Y-o-Y Growth Comparison, By Retinal Disease
7.2 Global Ophthalmic Disease Therapeutic Market Share Analysis, By Retinal Disease
7.3. Global Ophthalmic Disease Therapeutic Market Size and Forecast, By Retinal Disease
7.3.1 Glaucoma
7.3.2 Dry Eye Disease
7.3.3 Retinal Diseases
7.3.4 Allergy & Infections
7.3.5 Others
8. Global Ophthalmic Disease Therapeutic Market, By Distribution Channel
8.1 Y-o-Y Growth Comparison, By Distribution Channel
8.2 Global Ophthalmic Disease Therapeutic Market Share Analysis, By Distribution Channel
8.3 Global Ophthalmic Disease Therapeutic Market Size and Forecast, By Distribution Channel
8.3.1 Hospital Pharmacies
8.3.2. Retail & Online Pharmacies
8 Global Ophthalmic Disease Therapeutic Market, By Region
8.1 Global Ophthalmic Disease Therapeutic Market Share Analysis, By Region
8.2 Global Ophthalmic Disease Therapeutic Market Share Analysis, By Region
8.3 Global Ophthalmic Disease Therapeutic Market Size and Forecast, By Region
9 North America Ophthalmic Disease Therapeutic Market Analysis and Forecast (2022-2027)
9.1 Introduction
9.2 North America Ophthalmic Disease Therapeutic Market Share Analysis, By Drug Class
9.3 North America Ophthalmic Disease Therapeutic Market Size and Forecast, By Dosage Form
9.4 North America Ophthalmic Disease Therapeutic Market Size and Forecast, By Retinal Disease
9.5 North America Ophthalmic Disease Therapeutic Market Size and Forecast, By Distribution Channel
9.6 North America Ophthalmic Disease Therapeutic Market Size and Forecast, By Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
10 Europe Ophthalmic Disease Therapeutic Market Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 Europe Ophthalmic Disease Therapeutic Market Share Analysis, By Drug Class
10.3 Europe Ophthalmic Disease Therapeutic Market Size and Forecast, By Dosage Form
10.4 Europe Ophthalmic Disease Therapeutic Market Size and Forecast, By Retinal Disease
10.5 Europe Ophthalmic Disease Therapeutic Market Size and Forecast, By Distribution Channel
10.6 Europe Ophthalmic Disease Therapeutic Market Size and Forecast, By Country
10.6.1 Germany
10.6.2 France
10.6.3 UK
10.6.4. Rest of Europe
11 Asia Pacific Ophthalmic Disease Therapeutic Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Asia Pacific Ophthalmic Disease Therapeutic Market Share Analysis, By Drug Class
11.3 Asia Pacific Ophthalmic Disease Therapeutic Market Size and Forecast, By Dosage Form
11.4 Asia Pacific Ophthalmic Disease Therapeutic Market Size and Forecast, By Retinal Disease
11.5 Asia Pacific Ophthalmic Disease Therapeutic Market Size and Forecast, By Distribution Channel
11.6 Asia Pacific Ophthalmic Disease Therapeutic Market Size and Forecast, By Country
11.6.1 China
11.6.2 Japan
11.6.3 India
11.6.4. Rest of Asia Pacific
12 Latin America Ophthalmic Disease Therapeutic Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Latin America Ophthalmic Disease Therapeutic Market Share Analysis, By Drug Class
12.3 Latin America Ophthalmic Disease Therapeutic Market Size and Forecast, By Dosage Form
12.4 Latin America Ophthalmic Disease Therapeutic Market Size and Forecast, Retinal Disease
12.5 Latin America Ophthalmic Disease Therapeutic Market Size and Forecast, By Distribution Channel
12.6 Latin America Ophthalmic Disease Therapeutic Market Size and Forecast, Country
13 Middle East Ophthalmic Disease Therapeutic Market Analysis and Forecast (2022-2027)
13.1 Introduction
13.2 Middle East Ophthalmic Disease Therapeutic Market Share Analysis, By Drug Class
13.3 Middle East Ophthalmic Disease Therapeutic Market Size and Forecast, By Dosage Form
13.4 Middle East Ophthalmic Disease Therapeutic Market Size and Forecast, By Retinal Disease
13.5 Middle East Ophthalmic Disease Therapeutic Market Size and Forecast, By Distribution Channel
13.6 Middle East Ophthalmic Disease Therapeutic Market Size and Forecast, By Country
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Regeneron Pharmaceuticals Inc
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. AbbVie Inc
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Santen Pharmaceutical Co. Ltd
15.3.1 Overvie
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Novartis AG
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Bayer AG
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Viatris Inc
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 F. Hoffmann-La Roche Ltd
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Alcon
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Merck & Co., Inc.
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Pfizer Inc
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
